Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the “Guardian Angel of the Human Genome”

Learn more »

Clinical Trials at Dana-Farber and Beth Israel Deaconess / Harvard Cancer Centers

Learn more »

Prurisol for Psoriasis Planned- Phase 2/3 under FDA 505(b)(2)

Learn more »

Dr. Emil Frei: “What Cellceutix is doing with Kevetrin can lead to a groundbreaking moment in the world of oncology…”

Learn more »

Leading Antibiotic Technologies Licensed From University of Pennsylvania

Learn more »

Cellceutix Takes on Klebsiella Pneumoniae, One of the World’s Most Dangerous Superbugs

Learn more »

From the CEO’s Desk

The Best Is Yet To Come

Thank you for visiting the Cellceutix Corporation website. My name is Leo Ehrlich, Chief Executive Officer of Cellceutix. Cellceutix is a Beverly, Massachusetts-based clinical stage biotechnology company focused on discovering small molecule drugs for ...

Read More »

Our Technology

Kevetrin
Our technology - Kevetrin™ targets both MDM2-p53 and Rb-E2F pathways in tumor suppression.

Read more »

Prurisol
Our technology KM-133 acts through immune modulation and PRINS reduction

Read more »

Brilacidin
Our technology - Brilacidin is the first of a completely new class of antibiotics called defensin-mimetics

Read more »

Email Alerts

Sign Up to Receive Alerts on Cellceutix click here.

Clinical Trials

More information available at clinicaltrials.gov